Covid-19 New

More Info

Open access Aims and Scope Instructions Editorial Guidelines Licensing Copyright

Author's satisfaction with

  • Friendly and hassle-free publication process
  • Less production time of articles
  • Constructive peer-review
  • Enhancing journal reputation
  • Regular feedback system
  • Quick response to authors' queries

Read More

Recently Viewed

Development of qualitative GC MS method for simultaneous ide Modulation of atrial natriuretic peptide receptors in ovaria Prospective Coronavirus Liver Effects: Available Knowledge Clinical and Epidemiological Profile of Reversible Acute Kid Update on the Use of Mesenchymal Stem Cells in the Treatment

Read More

Most Viewed

Evaluation of Biostimulants Based on Recovered Protein Hydro Feasibility study of magnetic sensing for detecting single-n Physical activity can change the physiological and psycholog Pediatric Dysgerminoma: Unveiling a Rare Ovarian Tumor Prospective Coronavirus Liver Effects: Available Knowledge

Read More

Open Journals

Clinical Images

For Authors Guide For Authors Benefits For Authors Article Processing Charge How To Write a Scientific Paper How To Write a Review Article Short Communication
For Reviewers Benefits For Reviewers How To Review Thanks To Reviewers
For Editors Benefits For Editors Thanks To Editors

Abstract

Review Article

Multimodal treatment strategies in Huntington’s disease

Rajib Dutta*

Published: 15 July, 2021 | Volume 5 - Issue 2 | Pages: 072-082

Huntington’s disease (HD) is an incurable neurodegenerative disease that causes involuntary movements, emotional lability, and cognitive dysfunction. HD symptoms usually develop between ages 30 and 50, but can appear as early as 2 or as late as 80 years. Currently no neuroprotective and neurorestorative interventions are available. Early multimodal intervention in HD is only possible if the genetic diagnosis is made early. Early intervention in HD is only possible if genetic diagnosis is made at the disease onset or when mild symptoms manifest. Growing evidence and understanding of HD pathomechanism has led researchers to new therapeutic targets. Here, in this article we will talk about the multimodal treatment strategies and recent advances made in this field which can be used to target the HD pathogenesis at its most proximal level.

Read Full Article HTML DOI: 10.29328/journal.jnnd.1001054 Cite this Article Read Full Article PDF

Keywords:

Huntington’s disease; Genetic; Pathogenesis; Therapeutic; Multimodal; Treatment

References

  1. Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, et al. Huntington disease. Nat Rev Dis Primers. 2015; 1: 15005. PubMed: https://pubmed.ncbi.nlm.nih.gov/27188817/
  2. Finkbeiner S. Huntington's Disease. Cold Spring Harb Perspect Biol. 2011; 3: a007476. PubMed: https://pubmed.ncbi.nlm.nih.gov/21441583/
  3. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993 Mar 26; 72: 971-983. PubMed: https://pubmed.ncbi.nlm.nih.gov/8458085/
  4. Walker FO. Huntington's disease. Lancet. 2007 Jan 20; 369: 218-228. PubMed: https://pubmed.ncbi.nlm.nih.gov/17240289/
  5. Gilliam TC, Tanzi RE, Haines JL, Bonner TI, Faryniarz AG, et al. Localization of the Huntington's disease gene to a small segment of chromosome 4 flanked by D4S10 and the telomere. Cell. 1987; 50: 565-571. PubMed: https://pubmed.ncbi.nlm.nih.gov/2886227/
  6. Ghosh R, Tabrizi SJ. Huntington disease. Handb Clin Neurol. 2018; 147: 255-278. PubMed: https://pubmed.ncbi.nlm.nih.gov/29325616/
  7. Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, et al. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology. 2012; 78: 690-695. PubMed: https://pubmed.ncbi.nlm.nih.gov/22323755/
  8. Rubinsztein DC, Leggo J, Coles R, Almqvist E, Biancalana V, et al. Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet. 1996; 59: 16-22. PubMed: https://pubmed.ncbi.nlm.nih.gov/8659522/
  9. Kremer B, Almqvist E, Theilmann J, Spence N, Telenius H, et al. Sex-dependent mechanisms for expansions and contractions of the CAG repeat on affected Huntington disease chromosomes. Am J Hum Genet. 1995; 57: 343-350. PubMed: https://pubmed.ncbi.nlm.nih.gov/7668260/
  10. Ranen NG, Stine OC, Abbott MH, Sherr M, Codori AM, et al. Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease. Am J Hum Genet. 1995; 57: 593-602. PubMed: https://pubmed.ncbi.nlm.nih.gov/7668287/
  11. Trottier Y, Biancalana V, Mandel JL. Instability of CAG repeats in Huntington's disease: relation to parental transmission and age of onset. J Med Genet. 1994; 31: 377-382. PubMed: https://pubmed.ncbi.nlm.nih.gov/8064815/
  12. Myers RH, MacDonald ME, Koroshetz WJ, Duyao MP, Ambrose CM, et al. De novo expansion of a (CAG)n repeat in sporadic Huntington's disease. Nat Genet. 1993; 5: 168-173. PubMed: https://pubmed.ncbi.nlm.nih.gov/8252042/
  13. Semaka A, Creighton S, Warby S, Hayden MR. Predictive testing for Huntington disease: interpretation and significance of intermediate alleles. Clin Genet. 2006; 70: 283-294. PubMed: https://pubmed.ncbi.nlm.nih.gov/16965319/
  14. Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet. 1993; 4: 398-403. PubMed: https://pubmed.ncbi.nlm.nih.gov/8401589/
  15. Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium. Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease. Cell. 2015; 162: 516-526. PubMed: https://pubmed.ncbi.nlm.nih.gov/26232222/
  16. Rawlins MD, Wexler NS, Wexler AR, Tabrizi SJ, Douglas I, et al. The prevalence of huntington’s disease. Neuroepidemiology. 2016; 46: 144–153. PubMed: https://pubmed.ncbi.nlm.nih.gov/26824438/
  17. Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, et al. The incidence and prevalence of huntington’s disease: a systematic review and meta-analysis. Mov Disord. 2012; 27: 1083–1091. PubMed: https://pubmed.ncbi.nlm.nih.gov/22692795/
  18. Bashir H, Jankovic J. Treatment options for chorea. Expert Rev Neurother. 2018; 18: 51–63. PubMed: https://pubmed.ncbi.nlm.nih.gov/29120264/
  19. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in huntington’s disease. Physiol Rev.2010; 90: 905–981. PubMed: https://pubmed.ncbi.nlm.nih.gov/20664076/
  20. Arrasate M, Finkbeiner S. Protein aggregates in huntington’s disease. Exp Neurol. 2012; 238: 1–11. PubMed: https://pubmed.ncbi.nlm.nih.gov/22200539/
  21. Neueder A, Landles C, Ghosh R, Howland D, Myers RH, et al. The pathogenic exon 1 HTT protein is produced by incomplete splicing in huntington’s disease patients. Sci Rep. 2017; 7: 1307. PubMed: https://pubmed.ncbi.nlm.nih.gov/28465506/
  22. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet. 2003; 12: 1555–1567. PubMed: https://pubmed.ncbi.nlm.nih.gov/12812983/
  23. Slow EJ, Graham RK, Osmand AP, Devon RS, Lu G, et al. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad Sci U S A. 2005; 102: 11402–11407. PubMed: https://pubmed.ncbi.nlm.nih.gov/16076956/
  24. Sica RE. Could astrocytes be the primary target of an offending agent causing the primary degenerative diseases of the human central nervous system? A hypothesis. Med Hypotheses. 2015; 84: 481–489. PubMed: https://pubmed.ncbi.nlm.nih.gov/25697116/
  25. Fjodorova M, Louessard M, Li Z, De La Fuente DC, Dyke E, et al. CTIP2-Regulated Reduction in PKA-Dependent DARPP32 Phosphorylation in Human Medium Spiny Neurons: Implications for Huntington Disease. Stem Cell Reports. 2019; 13: 448-457. PubMed: https://pubmed.ncbi.nlm.nih.gov/31447328/
  26. Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in Huntington's disease [published correction appears in Lancet Neurol. 2017 Dec; 16: 954]. Lancet Neurol. 2017; 16: 837-847. PubMed: https://pubmed.ncbi.nlm.nih.gov/28920889/
  27. Crooke ST. Molecular Mechanisms of Antisense Oligonucleotides. Nucleic Acid Ther. 2017; 27: 70-77. PubMed: https://pubmed.ncbi.nlm.nih.gov/28080221/
  28. Du L, Kayali R, Bertoni C, Fike F, Hu H, et al. Arginine-rich cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum. Hum Mol Genet 2011; 20: 3151–3160. PubMed: https://pubmed.ncbi.nlm.nih.gov/21576124/
  29. Aguiar S, van der Gaag B, Cortese FAB. RNAi mechanisms in Huntington's disease therapy: siRNA versus shRNA. Transl Neurodegener. 2017; 6: 30. PubMed: https://pubmed.ncbi.nlm.nih.gov/29209494/
  30. Pfister EL, DiNardo N, Mondo E, Borel F, Conroy F, et al. Artificial miRNAs Reduce Human Mutant Huntingtin Throughout the Striatum in a Transgenic Sheep Model of Huntington's Disease. Hum Gene Ther. 2018; 29: 663-673. PubMed: https://pubmed.ncbi.nlm.nih.gov/29207890/
  31. Sah DW, Aronin N. Oligonucleotide therapeutic approaches for Huntington disease. J Clin Invest. 2011; 121: 500-507. PubMed: https://pubmed.ncbi.nlm.nih.gov/21285523/
  32. Boudreau RL, McBride JL, Martins I, Shen S, Xing Y, et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington’s disease mice. Mol Ther. 2009; 17: 1053–1063. PubMed: https://pubmed.ncbi.nlm.nih.gov/19240687/
  33. McBride JL, Pitzer MR, Boudreau RL, Dufour B, Hobbs T, et al. Preclinical safety of RNAi mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington’s disease. Mol Ther. 2011; 19: 2152–2162. PubMed: https://pubmed.ncbi.nlm.nih.gov/22031240/
  34. Qu Y, Liu Y, Noor AF, Tran J, Li R. Characteristics and advantages of adeno-associated virus vector-mediated gene therapy for neurodegenerative diseases. Neural Regen Res. 2019; 14: 931-938. PubMed: https://pubmed.ncbi.nlm.nih.gov/30761996/
  35. Merkel SF, Andrews AM, Lutton EM, Mu D, Hudry E, et al. Trafficking of adeno-associated virus vectors across a model of the blood-brain barrier; a comparative study of transcytosis and transduction using primary human brain endothelial cells. J Neurochem. 2017; 140: 216-230. PubMed: https://pubmed.ncbi.nlm.nih.gov/27718541/
  36. Dufour BD, Smith CA, Clark RL, Walker TR, McBride JL. Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in huntington’s disease mice. Mol Ther. 2014; 22: 797–810. PubMed: https://pubmed.ncbi.nlm.nih.gov/24390280/
  37. Matsuzaki Y, Konno A, Mochizuki R, Shinohara Y, Nitta K, et al. Intravenous administration of the adeno-associated virus-PHP.B. capsid fails to upregulate transduction efficiency in the marmoset brain. Neurosci Lett. 2018; 665: 182–188. PubMed: https://pubmed.ncbi.nlm.nih.gov/29175632/
  38. Marco S, Murillo A, Pérez-Otaño I. RNAi-Based GluN3A Silencing Prevents and Reverses Disease Phenotypes Induced by Mutant huntingtin. Mol Ther. 2018; 26: 1965-1972. PubMed: https://pubmed.ncbi.nlm.nih.gov/29914757/
  39. Matthes F, Massari S, Bochicchio A, Schorpp K, Schilling J, et al. Reducing Mutant Huntingtin Protein Expression in Living Cells by a Newly Identified RNA CAG Binder. ACS Chem Neurosci. 2018; 9: 1399-1408. PubMed: https://pubmed.ncbi.nlm.nih.gov/29506378/
  40. Sava V, Fihurka O, Khvorova A, Sanchez-Ramos J. Enriched chitosan nanoparticles loaded with siRNA are effective in lowering Huntington's disease gene expression following intranasal administration. Nanomedicine. 2020; 24: 102119. PubMed: https://pubmed.ncbi.nlm.nih.gov/31666200/
  41. Miniarikova J, Zimmer V, Martier R, Brouwers CC, Pythoud C, et al. AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease. Gene Ther. 2017; 24: 630-639. PubMed: https://pubmed.ncbi.nlm.nih.gov/28771234/
  42. Keskin S, Brouwers CC, Sogorb-Gonzalez M, Martier R, Depla JA, et al. AAV5-miHTT Lowers Huntingtin mRNA and Protein without Off-Target Effects in Patient-Derived Neuronal Cultures and Astrocytes. Mol Ther Methods Clin Dev. 2019; 15: 275-284. PubMed: https://pubmed.ncbi.nlm.nih.gov/31737741/
  43. Rinaldi C, Wood MJA. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol.2017; 14: 9–21. PubMed: https://pubmed.ncbi.nlm.nih.gov/29192260/
  44. Ionis Pharmaceuticals. IONIS-HTT Rx (RG6042) top-line data demonstrate significant reductions of disease-causing mutant huntingtin protein in people with huntington’s disease. 2019. http://ir.ionispharma.com/node/23401/pdf
  45. Datson NA, González-Barriga A, Kourkouta E, Weij R, van de Giessen J, et al. The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain. PLoS One. 2017; 12: e0171127. PubMed: https://pubmed.ncbi.nlm.nih.gov/28182673/
  46. Keeler AM, Sapp E, Chase K, Sottosanti E, Danielson E, et al. Cellular Analysis of Silencing the Huntington's Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140/Q140 Mice. J Huntingtons Dis. 2016; 5: 239-248. PubMed: https://pubmed.ncbi.nlm.nih.gov/27689620/
  47. Mathkar PP, Suresh D, Dunn J, Tom CM, Mattis VB. Characterization of Neurodevelopmental Abnormalities in iPSC-Derived Striatal Cultures from Patients with Huntington's Disease. J Huntingtons Dis. 2019; 8: 257-269. PubMed: https://pubmed.ncbi.nlm.nih.gov/31381521/
  48. Geary RS, Norris D, Yu R, Bennett CF. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev.2015; 87: 46–51. PubMed: https://pubmed.ncbi.nlm.nih.gov/25666165/
  49. Kim MS, Kini AG. Engineering and Application of Zinc Finger Proteins and TALEs for Biomedical Research. Mol Cells. 2017; 40: 533-541. PubMed: https://pubmed.ncbi.nlm.nih.gov/28835021/
  50. Mittelman D, Moye C, Morton J, Sykoudis K, Lin Y, et al. Zinc-finger directed double-strand breaks within CAG repeat tracts promote repeat instability in human cells. Proc Natl Acad Sci U S A. 2009; 106: 9607–9612. PubMed: https://pubmed.ncbi.nlm.nih.gov/19482946/
  51. Garriga-Canut M, Agustín-Pavón C, Herrmann F, Sánchez A, Dierssen M, et al. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proc Natl Acad Sci U S A. 2012; 109: E3136–45. PubMed: https://pubmed.ncbi.nlm.nih.gov/23054839/
  52. Cubbon A, Ivancic-Bace I, Bolt EL. CRISPR-Cas immunity, DNA repair and genome stability. Biosci Rep. 2018; 38: BSR20180457. PubMed: https://pubmed.ncbi.nlm.nih.gov/30209206/
  53. Pickar-Oliver A, Gersbach CA. The next generation of CRISPR-Cas technologies and applications. Nat Rev Mol Cell Biol. 2019; 20: 490-507. PubMed: https://pubmed.ncbi.nlm.nih.gov/31147612/
  54. Nambiar TS, Billon P, Diedenhofen G, Hayward SB, Taglialatela A, et al. Stimulation of CRISPR-mediated homology-directed repair by an engineered RAD18 variant. Nat Commun. 2019; 10: 3395. PubMed: https://pubmed.ncbi.nlm.nih.gov/31363085/
  55. Yang S, Chang R, Yang H, Zhao T, Hong Y, et al. CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of huntington’s disease. J Clin Invest. 2017; 127: 2719–2724. PubMed: https://pubmed.ncbi.nlm.nih.gov/28628038/
  56. Shin JW, Kim KH, Chao MJ, Atwal RS, Gillis T, et al. Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9. Hum Mol Genet. 2016; 25: 4566-4576. PubMed: https://pubmed.ncbi.nlm.nih.gov/28172889/
  57. Pan Y, Daito T, Sasaki Y, Chung YH, Xing X, et al. Inhibition of DNA Methyltransferases Blocks Mutant Huntingtin-Induced Neurotoxicity. Sci Rep. 2016; 21: 33766. PubMed: https://pubmed.ncbi.nlm.nih.gov/27649847/
  58. Luthi-Carter R, Taylor DM, Pallos J, Lambert E, Amore A, et al. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc Natl Acad Sci USA. 2010; 107: 7927–7932. PubMed: https://pubmed.ncbi.nlm.nih.gov/20378838/
  59. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington’s disease. Physiol Rev. 2010; 90: 905–981. PubMed: https://pubmed.ncbi.nlm.nih.gov/20664076/
  60. Chopra V, Quinti L, Kim J, Vollor L, Narayanan KL, et al. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models. Cell Rep. 2012; 2: 1492-1497. PubMed: https://pubmed.ncbi.nlm.nih.gov/23200855/
  61. Jeong H, Then F, Melia TJ Jr, Mazzulli JR, Cui L, et al. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 2009; 137: 60–72. PubMed: https://pubmed.ncbi.nlm.nih.gov/19345187/
  62. Zhang F, Wang S, Gan L, Vosler PS, Gao Y, et al. Protective effects and mechanisms of sirtuins in the nervous system. Prog Neurobiol 2011; 95: 373–395. PubMed: https://pubmed.ncbi.nlm.nih.gov/21930182/
  63. Pallos J, Bodai L, Lukacsovich T, Purcell JM, Steffan JS, et al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington’s disease. Hum Mol Genet 2008; 17: 3767–3775. PubMed: https://pubmed.ncbi.nlm.nih.gov/18762557/
  64. Napper AD, Hixon J, McDonagh T, Keavey K, Pons JP, et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SirT1. J Med Chem 2005; 48: 8045–854. PubMed: https://pubmed.ncbi.nlm.nih.gov/16335928/
  65. Smith MR, Syed A, Lukacsovich T, Purcell J, Barbaro BA, et al. Sirtuin 1 inhibition alleviates pathology in multiple animal and cell models of Huntington’s disease. Hum Mol Genet 2014; 23: 2995–3007. PubMed: https://pubmed.ncbi.nlm.nih.gov/24436303/
  66. Reilmann R, Squitieri F, Priller J, et al. N02 Safety And Tolerability Of Selisistat For The Treatment Of Huntington’s Disease: Results From A Randomised, Double-blind, Placebo-controlled Phase Ii Trial. J Neurol Neurosurg Psychiatry. 2014; 85: A102.
  67. Deb A, Frank S, Testa CM. New symptomatic therapies for Huntington disease. Handb Clin Neurol. 2017; 144: 199-207. PubMed: https://pubmed.ncbi.nlm.nih.gov/28947118/
  68. Johanssen T, Suphantarida N, Donnelly PS, Liu XM, Petrou S, et al. PBT2 inhibits glutamate-induced excitotoxicity in neurons through metal-mediated preconditioning. Neurobiol Dis. 2015; 81: 176-185. PubMed: https://pubmed.ncbi.nlm.nih.gov/25697105/
  69. Huntington Study Group Reach 2HD Investigators. Safety, tolerability, and efficacy of PBT2 in huntington’s disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2015; 14: 39–47. PubMed: https://pubmed.ncbi.nlm.nih.gov/25467848/
  70. Prana Biotech. 2015. FDA end of phase 2 status update. 2019. http://pranabio.com/wp-content/uploads/2015/02/150213_FDA-notification-FINAL.pdf
  71. Rocha NP, Ribeiro FM, Furr-Stimming E, Teixeira AL. Neuroimmunology of Huntington's Disease: Revisiting Evidence from Human Studies. Mediators Inflamm. 2016; 2016: 8653132. PubMed: https://pubmed.ncbi.nlm.nih.gov/27578922/
  72. Crotti A, Benner C, Kerman BE, Gosselin D, Lagier-Tourenne C, et al. Mutant huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat Neurosci. 2014; 17: 513–521. PubMed: https://pubmed.ncbi.nlm.nih.gov/24584051/
  73. Garcia-Miralles M, Yusof NABM, Tan JY, Radulescu CI, Sidik H, et al. Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease. Mol Neurobiol. 2019; 56: 4464-4478. PubMed: https://pubmed.ncbi.nlm.nih.gov/30334188/
  74. Ellrichmann G, Blusch A, Fatoba O, Brunner J, Reick C, et al. Laquinimod treatment in the R6/2 mouse model Sci Rep. 2017; 7: 4947. PubMed: https://pubmed.ncbi.nlm.nih.gov/28694434/
  75. Garcia-Miralles M, Hong X, Tan LJ, Caron NS, Huang Y, et al. Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease. Sci Rep. 2016; 6: 31652. PubMed: https://pubmed.ncbi.nlm.nih.gov/27528441/
  76. Ehrnhoefer DE, Caron NS, Deng Y, Qiu X, Tsang M, et al. Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons. Exp Neurol. 2016; 283: 121-128. PubMed: https://pubmed.ncbi.nlm.nih.gov/27296315/
  77. Rodrigues FB, Wild EJ. Huntington's Disease Clinical Trials Corner: August 2018. J Huntingtons Dis. 2018; 7: 279-286. PubMed: https://pubmed.ncbi.nlm.nih.gov/30103342/
  78. Rodrigues FB, Ferreira JJ, Wild EJ. Huntington's Disease Clinical Trials Corner: June 2019. J Huntingtons Dis. 2019; 8: 363-371. PubMed: https://pubmed.ncbi.nlm.nih.gov/31381524/
  79. https://huntingtonsdiseasenews.com/2018/04/26/aan2018-phase-2-trial-targets-loss-brain-volume-huntingtons/
  80. Jimenez-Sanchez M, Licitra F, Underwood BR, Rubinsztein DC. Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies. Cold Spring Harb Perspect Med. 2017; 7: a024240. PubMed: https://pubmed.ncbi.nlm.nih.gov/27940602/
  81. Sahlholm K, Århem P, Fuxe K, Marcellino D. The dopamine stabilizers ACR16 and (-)-OSU6162 display nanomolar affinities at the σ-1 receptor. Mol Psychiatry. 2013; 18: 12-14. PubMed: https://pubmed.ncbi.nlm.nih.gov/22349783/
  82. Waters S, Tedroff J, Ponten H, Klamer D, Sonesson C, et al. Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease. J Huntingtons Dis. 2018; 7: 1-16. PubMed: https://pubmed.ncbi.nlm.nih.gov/29480206/
  83. Tang TS, Slow E, Lupu V, Stavrovskaya IG, Sugimori M, et al. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in huntington’s disease. Proc Natl Acad Sci USA. 2005; 102: 2602–2607. PubMed: https://pubmed.ncbi.nlm.nih.gov/15695335/
  84. Hyrskyluoto A, Pulli I, Törnqvist K, Ho TH, Korhonen L, et al. Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced celldegeneration: involvement of calpastatin and the NF-κB pathway.Cell Death Dis. 2013; 4: e646. PubMed: https://pubmed.ncbi.nlm.nih.gov/23703391/
  85. Smith-Dijak AI, Nassrallah WB, Zhang LYJ, Geva M, Hayden MR, et al. Impairment and Restoration of Homeostatic Plasticity in Cultured Cortical Neurons From a Mouse Model of Huntington Disease. Front Cell Neurosci. 2019; 13: 209. PubMed: https://pubmed.ncbi.nlm.nih.gov/31156395/
  86. Eddings CR, Arbez N, Akimov S, Geva M, Hayden MR, et al. Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor. Neurobiology of Disease. 2019; 129; 118–129. PubMed: https://pubmed.ncbi.nlm.nih.gov/31108174/
  87. Kusko R, Dreymann J, Ross J, et al. Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse. Mol Neurodegener. 2018; 13: 25.
  88. Garcia-Miralles M, Geva M, Tan JY, Mohammad Yusof NABM, Cha Y, et al. Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. JCI Insight. 2017; 2: e95665. PubMed: https://pubmed.ncbi.nlm.nih.gov/29212949/
  89. Reilmann R, McGarry A, Grachev ID, et al. Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol. 2019; 18: 165-176. PubMed: https://pubmed.ncbi.nlm.nih.gov/30563778/
  90. Jokinen EM, Postila PA, Ahinko M, Niinivehmas S, Pentikäinen OT. Fragment- and negative image-based screening of phosphodiesterase 10A inhibitors. Chem Biol Drug Des. 2019; 94: 1799-1812. PubMed: https://pubmed.ncbi.nlm.nih.gov/31260165/
  91. Diggle CP, Sukoff Rizzo SJ, Popiolek M, et al. Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy. Am J Hum Genet. 2016; 98: 735-743. PubMed: https://pubmed.ncbi.nlm.nih.gov/27058446/
  92. Harada A, Suzuki K, Kimura H. TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington's Disease. J Pharmacol Exp Ther. 2017; 360: 75-83.
  93. Beaumont V, Zhong S, Lin H, Hinttala R, Schülke JP, et al. Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington's Disease Models. Neuron. 2016; 92: 1220-1237.
  94. Chang WT, Puspitasari F, Garcia-Miralles M, Yeow LY, Tay HC, et al. Connectomic imaging reveals Huntington-related pathological and pharmaceutical effects in a mouse model. NMR Biomed. 2018; 31: e4007. PubMed: https://pubmed.ncbi.nlm.nih.gov/30260561/
  95. Chidambaram SB, Vijayan R, Sekar S, Mani S, Rajamani B, et al. Simultaneous blockade of NMDA receptors and PARP-1 activity synergistically alleviate immunoexcitotoxicity and bioenergetics in 3-nitropropionic acid intoxicated mice: Evidences from memantine and 3-aminobenzamide interventions. Eur J Pharmacol. 2017; 803: 148-158. PubMed: https://pubmed.ncbi.nlm.nih.gov/28322842/
  96. Mahfooz K, Marco S, Martínez-Turrillas R, Raja MK, Pérez-Otaño I, et al. GluN3A promotes NMDA spiking by enhancing synaptic transmission in Huntington's disease models. Neurobiol Dis. 2016; 93: 47-56. PubMed: https://pubmed.ncbi.nlm.nih.gov/27072890/
  97. Arbez N, Roby E, Akimov S, Eddings C, Ren M, et al. Cysteamine Protects Neurons from Mutant Huntingtin Toxicity. J Huntingtons Dis. 2019; 8: 129-143. PubMed: https://pubmed.ncbi.nlm.nih.gov/30856117/
  98. Borrell-Pagès M, Canals JM, Cordelières FP, Parker JA, Pineda JR, et al. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest. 2006; 116: 1410-1424. PubMed: https://pubmed.ncbi.nlm.nih.gov/16604191/
  99. Verny C, Bachoud-Lévi AC, Durr A, Goizet C, Azulay JP, et al. A randomized, double-blind, placebo-controlled trial evaluating cysteamine in Huntington's disease. Mov Disord. 2017; 32: 932-936. PubMed: https://pubmed.ncbi.nlm.nih.gov/28436572/
  100. Colpo GD, Ascoli BM, Wollenhaupt-Aguiar B, Pfaffenseller B, Silva EG, et al. Mesenchymal stem cells for the treatment of neurodegenerative and psychiatric disorders. An Acad Bras Cienc. 2015; 87: 1435–1449. PubMed: https://pubmed.ncbi.nlm.nih.gov/26247151/
  101. Wu TT, Su FJ, Feng YQ, Liu B, Li MY, et al. Mesenchymal stem cells alleviate AQP-4-dependent glymphatic dysfunction and improve brain distribution of antisense oligonucleotides in BACHD mice. Stem Cells. 2020; 38: 218-230. PubMed: https://pubmed.ncbi.nlm.nih.gov/31648394/
  102. Elbaz EM, Helmy HS, El-Sahar AE, Saad MA, Sayed RH. Lercanidipine boosts the efficacy of mesenchymal stem cell therapy in 3-NP-induced Huntington's disease model rats via modulation of the calcium/calcineurin/NFATc4 and Wnt/β-catenin signalling pathways. Neurochem Int. 2019; 131: 104548. PubMed: https://pubmed.ncbi.nlm.nih.gov/31539560/
  103. Yu-Taeger L, Stricker-Shaver J, Arnold K, Bambynek-Dziuk P, Novati A, et al. Intranasal Administration of Mesenchymal Stem Cells Ameliorates the Abnormal Dopamine Transmission System and Inflammatory Reaction in the R6/2 Mouse Model of Huntington Disease. Cells. 2019; 8: 595. PubMed: https://pubmed.ncbi.nlm.nih.gov/31208073/
  104. Cho IK, Hunter CE, Ye S, Pongos AL, Chan AWS. Combination of stem cell and gene therapy ameliorates symptoms in Huntington's disease mice. NPJ Regen Med. 2019; 4: 7. PubMed: https://pubmed.ncbi.nlm.nih.gov/30937182/
  105. Eskandari N, Boroujeni ME, Abdollahifar MA, Piryaei A, Khodagholi F, et al. Transplantation of human dental pulp stem cells compensates for striatal atrophy and modulates neuro-inflammation in 3-nitropropionic acid rat model of Huntington's disease. 2020. Neurosci Res. 2020; S0168-0102(20)30505-8. PubMed: https://pubmed.ncbi.nlm.nih.gov/33359180/
  106. Bayat AH, Saeidikhoo S, Ebrahimi V, Mesgar S, Joneidi M, et al. Bilateral striatal transplantation of human olfactory stem cells ameliorates motor function, prevents necroptosis-induced cell death and improves striatal volume in the rat model of Huntington's disease. J Chem Neuroanat. 2021; 112: 101903. PubMed: https://pubmed.ncbi.nlm.nih.gov/33278568/
  107. Yoon Y, Kim HS, Hong CP, Li E, Jeon I, et al. Neural Transplants From Human Induced Pluripotent Stem Cells Rescue the Pathology and Behavioral Defects in a Rodent Model of Huntington's Disease. Front Neurosci. 2020; 14: 558204. PubMed: https://pubmed.ncbi.nlm.nih.gov/33071737/
  108. Besusso D, Schellino R, Boido M, Belloli S, Parolisi R, et al. Stem Cell-Derived Human Striatal Progenitors Innervate Striatal Targets and Alleviate Sensorimotor Deficit in a Rat Model of Huntington Disease. Stem Cell Reports. 2020; 14: 876-891. PubMed: https://pubmed.ncbi.nlm.nih.gov/32302555/
  109. Giampà C, Alvino A, Magatti M, Silini AR, Cardinale A, et al. Conditioned medium from amniotic cells protects striatal degeneration and ameliorates motor deficits in the R6/2 mouse model of Huntington's disease. J Cell Mol Med. 2019; 23: 1581-1592. PubMed: https://pubmed.ncbi.nlm.nih.gov/30585395/
  110. Adil MM, Gaj T, Rao AT, Kulkarni RU, Fuentes CM, et al. hPSC-Derived Striatal Cells Generated Using a Scalable 3D Hydrogel Promote Recovery in a Huntington Disease Mouse Model. Stem Cell Reports. 2018; 10: 1481-1491. PubMed: https://pubmed.ncbi.nlm.nih.gov/29628395/
  111. Ebrahimi MJ, Aliaghaei A, Boroujeni ME, Khodagholi F, Meftahi G, et al. Human Umbilical Cord Matrix Stem Cells Reverse Oxidative Stress-Induced Cell Death and Ameliorate Motor Function and Striatal Atrophy in Rat Model of Huntington Disease. Neurotox Res. 2018; 34: 273-284. PubMed: https://pubmed.ncbi.nlm.nih.gov/29520722/
  112. Zhu G, Geng X, Tan Z, Chen Y, Zhang R, et al. Characteristics of Globus Pallidus Internus Local Field Potentials in Hyperkinetic Disease. Front Neurol. 2018; 9: 934. PubMed: https://pubmed.ncbi.nlm.nih.gov/30455666/
  113. Ferrea S, Groiss SJ, Elben S, Hartmann CJ, Dunnett SB, et al. Pallidal deep brain stimulation in juvenile Huntington's disease: local field potential oscillations and clinical data. J Neurol. 2018; 265: 1573-1579. PubMed: https://pubmed.ncbi.nlm.nih.gov/29725840/
  114. Zittel S, Tadic V, Moll CKE, Bäumer T, Fellbrich A, et al. Prospective evaluation of Globus pallidus internus deep brain stimulation in Huntington's disease. Parkinsonism Relat Disord. 2018; 51: 96-100. PubMed: https://pubmed.ncbi.nlm.nih.gov/29486999/
  115. Gonzalez V, Cif L, Biolsi B, Seychelles A, Sanrey E, et al. Deep brain stimulation for Huntington’s disease: long-term results of a prospective open label study. J Neurosurg. 2014; 121: 114–122. PubMed: https://pubmed.ncbi.nlm.nih.gov/24702329/
  116. Wojtecki L, Groiss SJ, Ferrea S, Elben S, Hartmann CJ, et al. A prospective pilot trial for pallidal deep brain stimulation in huntington’s disease. Front Neurol. 2015; 6: 177. PubMed: https://pubmed.ncbi.nlm.nih.gov/26347707/
  117. Yin Z, Bai Y, Zhang H, Liu H, Hu W, et al. An individual patient analysis of the efficacy of using GPi-DBS to treat Huntington's disease. Brain Stimul. 2020; 13: 1722-1731. PubMed: https://pubmed.ncbi.nlm.nih.gov/33038596/
  118. Sanrey E, Macioce V, Gonzalez V, Cif L, Cyprien F, et al. Does pallidal neuromodulation influence cognitive decline in Huntington's disease? J Neurol. 2021; 268: 613-622. PubMed: https://pubmed.ncbi.nlm.nih.gov/32886253/
  119. Lee M, Im W, Kim M. Exosomes as a potential messenger unit during heterochronic parabiosis for amelioration of Huntington's disease. Neurobiol Dis. 2021; 155: 105374. PubMed: https://pubmed.ncbi.nlm.nih.gov/33940179/
  120. Drew CJG, Sharouf F, Randell E, Brookes-Howell L, Smallman K, et al. Protocol for an open label: phase I trial within a cohort of foetal cell transplants in people with Huntington's disease. Brain Commun. 2021; 3: fcaa230. PubMed: https://pubmed.ncbi.nlm.nih.gov/33543141/

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Contact

Editorial Office Emails:

info@hspioa.org

amelia.sandra@hspioa.us

elena.maya@hspioa.us

Select by Volume & Issue

Submit Manuscript Information for Authors Advisory Board Rss Feed Articles Rss Feed

Most Viewed Keywords

University/Institution

Select and search by University/Institution.

Articles by Country

Select and search by country to get related articles.

Testmonials

I would like to thank JPRA for taking this decision. I understand the effort it represents for you. I'm truly happy to have the paper published in JPRA. And I'll certainly consider JPRA for my next publications as I was satisfied of the service provided, the efficiency and promptness of the interactions we had.

Emmanuel BUSATO

Publishing with the International Journal of Clinical and Experimental Ophthalmology was a rewarding experience as review process was thorough and brisk. Their visibility online is second to none as their published articles appear in all search engines. I will encourage researchers to publish with them.

Elizabeth Awoyesuku

“The choice to submit the forensic case study to the Journal of Addiction Therapy and Research was dictated by the match between the content and the potential readership. The publication process proved to be expedient and we were provided with constructive feedback from reviewers. The final article layout is attractive and conforms to standards. All-in-all, it has been a rewarding process.”

Elisabeth H Wiig

Archives of Vascular Medicine is one of the top class journal for vascular medicine with highly interesting topics. You did a professional and great Job!

Elias Noory

Thank you very much. I think the review process and all of what concerns the administration of the publication concerning our paper has been excellent. The nice and quick answers have been very good I think.

Doris Nilsson

Journal of Pulmonary and Respiratory Research is good journal for respiratory research purposes. It takes 2-3 weeks maximum for review of the manuscript to get published and any corrections to be made in the manuscript. It needs good articles and studies to get publish in the respiratory medicine. I am really glad that this journal editors helped me to get my case report published.

Divya Khanduja

Thanks you and your colleague for the great help for our publication. You always provide prompt responses and high quality of service. I am so happy to have you working with me. Thanks again!

Diana (Ding) Dai

Service and process were excellent as was the “look” of the article when published.

Deane Waldman

Great, thank you! It was very efficient working w/ your group. Very thorough reviews (i.e., plagiarism, peer, etc.). Would certainly recommend that future authors consider working w/ your group.

David W Brett

Your services are very good

Chukwuka Ireju Onyinye

I very much appreciate the humanitarian services provided in my stead by this journal/publisher. It exhibits total absence of editorial impertinence. As an Author, I have been guided to have a fruitful experience. The editorial care is highly commendable.

Chrysanthus Chukwuma

"An amazing experience with the Journal of Advanced Pediatrics and Child Health. Very fast blind review with pertinent corrections and suggestions. I highly recommand both the journal and the editor."

Chaimae Khairoun

The submission is very easy and the time from submission to response from the reviewers is short. Correspondence with the journal is nice and rapid.

Catrin Henriksson

The Clinical Journal of Obstetrics and Gynecology is an open access journal focused on scientific knowledge publication with emphasis laid on the fields of Gynecology and Obstetrics. Their services toward us have been encouraging through their kindness and respect. Great consideration has been given to us as young budding researchers and we are very grateful for this.

Carole Assontsa

During the process your positive communication, prompt feedback and professional approach is very highly appreciated. We would like to thank you very much for your support.

Can Vuran

I do appreciate for your service including submission, analysis, review, editorial and publishing process. I believe these esteemed journal enlighten the science with its high-quality personel.

Bora Uysal

I am very much pleased with the fast track publication by your reputed journal's editorial team. It is really helpful for researchers like me from developing nations. I strongly recommend your journal for publication.

Badri Kumar Gupta

It has been a fabulous journey writing articles for your journal because of the encouragement you people provide for writers from developing nations like India. Kindly continue the same. Looking forward for a long term association.

Badareesh Lakshminarayana

Many thanks for publishing my article in your great journal and the friendly and hassle-free publication process, the constructive peer-review, the regular feedback system, and the Quick response to any queries.

Azab Elsayed Azab

I would like to thank this journal for publishing my Research Article. Something I really appreciate about this journal is, they did not take much time from the day of Submission to the publishing date. Looking forward to have more publications in future.

Ayush Chandra

Submission of paper was smooth, the review process was fast. I had excellent communication and on time response from the editor.

Ayokunle Dada

Your service is very good and fast reply, also your service understand our situation and support us to publication our articles.

Ayman M Abu Mustafa

Really good service with prompt response. Looking forward to having long lasting relationship with your journal

Avishek Bagchi

Your service is excellent. Processing and editing were very fast. I hope to publish more of my works in your journal.

Ausraful Islam

I wanna to thank Clinical Journal of Nursing Care and Practice for its effort to review and publish my manuscript. This is reputable journal. Thank you!

Atsedemariam Andualem

“It was a delightful experience publishing my manuscript with the Clinical Journal of Obstetrics and Gynecology. They offered me lots of opportunities I never had from most publishing houses and their prompt services are greatly appreciated.”

Asafo Jones

I hope to ability to make some new investigation and publish in Your Company in future.

Artur Stopyra

I like the quality of the print & overall service. The paper looks quite impressive. Hope this will attract interested readers. All of you have our best wishes for continued success.

Arshad Khan

Your big support from researchers around the world is the best appreciation from your scientific teams. We believe that there should be no barrier in science and you make it real and this motto come true.

Arefhosseinir Rafi

Your journal co-operation is very appreciable and motivational. I am really thankful to your journal and team members for the motivation and collaboration to publish my work.

Assistant Professor, UCLAS Uttaranchal University, Dehradun, India

Archna Dhasmana

I am glad to submit the article to Heighten Science Publications as it has a very smooth and fast peer-review process, which enables the researchers to communicate their work on time.

Anupam M

This is to specify that I have had an extensive and detailed interaction with the Editorial team of Annals of Clinical Gastroenterology and Hepatology, USA, lasting over a significant period of time. My interaction has been extremely pleasant, especially with Ms Allie Smith, as I find the communication quite inspiring and crystal clear. The attitude of aforesaid individuals is quite helpful and guiding in pertinent instances. It has been a commemorative journey so far working with the Journal and I hope that the symbiosis will continue, evolve and flourish in the forthcoming years. I wish the journal, related personnel and aforementioned individuals a fruitful, successful run.

New Delhi, India

Anubha Bajaj

We appreciate the fact that you decided to give us full waiver for the applicable charges and approve the final version. You did an excellent job preparing the PDF version. Of course we will consider your magazine for our future submissions and we will pay the applicable fees then.

Anna Dionysopoulou

''Co-operation of Archives of Surgery and Clinical Research journal is appreciable. I'm impressed at the promptness of the publishing staff and the professionalism displayed. Thank you very much for your support, help and encouragement.''

Anıl Gokce

Congratulations for the excellence of your journal and high quality of its publications.

Angel MARTIN CASTELLANOS

The service from the journal staff has been excellent.

Andy Smith

I was very pleased with the quick editorial process. We are sure that our paper will have great visibility, among other things due to its open access. We believe in science accessible to all.

Anderson Fernando de Souza

It was a great experience publishing through JCICM. The article has reached out to several institutions. Appreciate your professional work. Hope to work with you again

Anas Wardeh

Publishing an article is a long process, but working with your publication department made things go smoothly, even though the process took exactly 5 months from the time of submitting the article till the time I have favourable response, the missing part is the peer review details, which is essential in self auditing and future improvement, overall experience was excellent giving your understanding of the situation of lack of financial institution support.

Anas Diab

I think that Heighpubs very good. You are very helpful. Thank you for everything.

Ana Ribeiro

Regarding to be services, we note that are work with high standards of professionalism translated into quick response, efficiency which makes communication accessible. Furthermore, I believe to be much inviting for the submission of future works for publication purposes.

Amélia João Alice Nkutxi

I would like to mention that I had a wonderful experience working with HSPI. The whole process right from manuscript submission to peer review till the publication of the article was very prompt & efficient. I wish you good luck for the future.

Amarjeet Gambhir

Once I submitted the manuscript, the response time of the reviewers was very fast. The fine-tuning of the galley proof was likewise prompt. I believe the journal provide a valuable outlet to disseminate physical rehabilitation scientific knowledge to the clinical community. Respectfully. Dr. Alon

Alon

We really appreciate and thanks the full waiver you provide for our article. We happy to publish our paper in your journal. Thank you very much for your good support and services.

Ali Abusafia

It was a real pleasure working with your team. The review was done fast, and it was very clear, the editing was flawless, the article was published quickly compared to other journals, and everyone was understanding and helpful. I will gladly recommend this journal to my acquaintances in academia.

Alexandra Cozma

To the editorial team at HSPI and the Journal of Clinical Nephrology: Thank you so much for your hard work and collaboration in bringing our article to life. Your staff was responsive, flexible, and communicative and made the process smooth and easy. Thank you!

Alejandro Munoz

Dear colleagues! I am satisfied with our cooperation with you. Your service is at a high level. I hope for a future relationship. Let me know if I can get a paper version of the magazine with my articles from you. I see them on the Internet.

Aksenov V.V

"This is my first time publishing with the journal/publisher. I am impressed at the promptness of the publishing staff and the professionalism displayed. Thank you for encouraging young researchers like me!"

Ajite Kayode

I want to thank you for our collaboration. You were fast and effective with a positive spirit of teamwork. I am truly excited from our collaboration. You were like always fast, efficient and accurate. I hope that in the near future we will collaborate again.

Aikaterini Solomou

In my opinion, you provide a very fast and practical service.

Ahmet Eroglu

Great, We are too comfortable with the process including the peer review process and quality. But, the journal should be indexed in different databases such scopus.

Afework Edmealem

We really appreciate your efforts towards our article, the professional way you handle our request for exemption from charges. It was a great honor for us to publish in your magazine.

Achraf elbakkaly

I really liked the ease of submitting my manuscript in the HSPI journal. Further, the peer review was timely completed and I was communicated the final decision on my manuscript within 10 days of submission which is really appreciable. I strongly recommend all the scientists and researchers to submit their work in this journal”

Abu Bashar

My candid opinion is that the service you render is second to none. My favourite part is the prompt response to issue, really i value that.

Abiodun Akanbi Adeogun

Thank you very much for accepting our manuscript in your journal “International Journal of Clinical Virology”. We are very thankful to the esteemed team for timely response and quick review process. The editorial team of International Journal of Clinical Virology is too cooperative and well-mannered during the publication process. We are hopeful to publish many quality papers in your journal and I suggest the International Journal of Clinical Virology to all of my colleagues, researchers and friends to publish their research here.

Abdul Baset

I, Muhammad Sarwar Khan, am serving as Editor on Archives of Biotechnology and Biomedicine (ABB). I submitted an editorial titled, 'Edible vaccines to combat Infectious Bursal Disease of poultry' for publication in ABB. After submitting the manuscript; the services rendered by the management and technical personnel to handle and process the manuscript were marvelous. Plagiarism report was shared with me with complements before reviewers' comments, All steps including article processing and service charges were well taken care of keeping in view the author's interest/preference. All together, it was an encouraging and wonderful experience working with ABB personnel.

University of Agriculture, Pakistan

Muhammad Sarwar Khan

Your journal has accomplished its intended mission of providing very effective and efficient goals in dealing with submissions, conducting the reviewing process and in publishing accepted manuscripts in a timely manner. Keep up the great work and services that you provide.

University of Jacqmar, Inc., USA

John St. Cyr

I am to express my view that Heighten Science Publications are reliable quick even after peer review process. I hope and wish the publications will go a long way in disseminating science to many interested in scientific research.

College of Fisheries, CAU(I), Tripura, India

Ajit Kumar Roy

The Journal Clinical Nephrology provides a good opportunity for readers to stay updated in the field of clinical nephrology. Additionally - it provides a good opportunity for authors to publish their work. 1. Publication of the accepted manuscripts is sufficiently rapid. 2. The trust factor between the journal and me, as an author, is very important and well preserved. 3. Peer review process very rapid and effective.

Assaf Harofeh Medical Center, Israel

Leonid Feldman

In 2017, I submitted a manuscript to the journal Archives of Biotechnology and Biomedicine belonging to Heighten Science Publications Corporation. Within one week I already received the response from the editor. All processing steps were really fast so in terms of a speedy publication I can particularly recommend the journal Archives of Biotechnology and Biomedicine. The responsible contact person of the journal was always available, which gives a trustworthy impression to the author. Also the peer review process was clear and constructive. So from my experience with Heighten Science Publications Corporation I can recommend publishing there.

University of Tubingen, Germany

Yvonne Mast

We thank to the heighten science family, who speed up the publication of our article and provide every support.

Mehmet Besir

The services of the journal were excellent. The most important thing for an author is the speed of the peer review which was really fast here. They returned in a few days and immediately replied all of my questions. I want to refer this platform to all scholars. Many thanks.

Eastern Mediterranean University, Cyprus

Zehra Guchan TOPCU

Thank you for your attitude and support. I am sincerely grateful to you and the entire staff of the magazine for the high professionalism and fast quality work. Thank you very much!

USA

Igor Klepikov

Thank you and your company for effective support of authors which are very much dependable on the funds gambling for science in the different countries of our huge and unpredictable world. We are doing our work and should rely on a teams like Galley Proof-HSPC. Great success to all of you for the 2019th! Be well all the year long.

Russia

Victor V Apollonov

The editorial process was quickly done. The galley proof was sent within a week after being accepted for publication. The editorial team was very helpful and responded promptly.

India

Rohit Kulshrestha

Publishing with the International Journal of Clinical and Experimental Ophthalmology was a rewarding experience as review process was thorough and brisk. Their visibility online is second to none as their published articles appear in all search engines. I will encourage researchers to publish with them.

University of Port Harcourt Teaching Hospital, Nigeria

Dr. Elizabeth A Awoyesuku

"It was a pleasure to work with the editorial team of the journal on the submission of the manuscript. The team was professional, fast, and to the point".

NC A&T State University, USA

Moran Sciamama-Saghiv

Submission of paper was smooth, the review process was fast. I had excellent communication and on time response from the editor.

Ekiti State University Teaching Hospital, Nigeria

Ayokunle Dada

I am delighted and satisfied with. Heighten Science Publications as my manuscript was thoroughly assessed and published on time without delay. Keep up the good work.

Ido-Ekiti/Afe Babalola University, Nigeria

Dr. Shuaib Kayode Aremu

"This is my first time publishing with the journal/publisher. I am impressed at the promptness of the publishing staff and the professionalism displayed. Thank you for encouraging young researchers like me!"

Ekiti State University, Nigeria

Adebukola Ajite

I wanna to thank clinical journal of nursing care and practice for its effort to review and publish my manuscript. This is reputable journal. Thank you!

Wollo University, Ethiopia

Atsedemariam Andualem

We appreciate your approach to scholars and will encourage you to collaborate with your organization, which includes interesting and different medical journals. With the best wishes of success, creativity and joy in life, prosperity in the medical field.

Ivano- Frankivsk National Medical University, Ukraine

Nataliya Kitsera

Thank you very much for your support and encouragement. I am truly impressed by your tolerance and support. Thank you very much

Diaverum: PADC, Jeddah, Saudi Arabia

Nasrulla Abutaleb

You are such a nice person. Your journal co-operation is very appreciable and motivational.

Department of Biotechnology, Uttaranchal college of Applied and Life Sciences, Uttaranchal University, Dehradun, Uttarakhand, India

Archna Dhasmana

“Mobile apps and wearable technology are becoming ubiquitous in our environment. Their integration with healthcare delivery is just beginning to take shape. The early results are promising and the possibilities great."

BS, PharmD., MBA, CPHIMS, FHIMSS, Adjunct Professor, Global Healthcare Management, MCPHS University, Chief Strategy Offi cer, MedicaSoft, Senior Advisor, National Health IT (NHIT) Collaborative for Underserved, New York HIMSS, National Liaison, Health 2.0 Boston, Past Chair, Chair Innovation, USA

Helen Figge

“The choice to submit the forensic case study to the Journal of Addiction Therapy and Research was dictated by the match between the content and the potential readership. The publication process proved to be expedient and we were provided with constructive feedback from reviewers. The final article layout is attractive and conforms to standards. All-in-all, it has been a rewarding process.”

Ph.D, Boston University Department of Communication Sciences and Disorders and Knowledge Research Institute, Inc., 2131 Reflection Bay Drive, Arlington, Texas 76013, USA

Elisabeth H. Wiig

The service is nice and the time of processing the application is fast.

Department of Neurosurgery, Queen Elizabeth Hospital, Hong Kong

Long Ching

Your service is very good and fast reply, Also your service understand our situation and support us to publication our articles.

Palestine College of Nursing, Khan Younis, Gaza Strip, Palestine

Ayman M Abu Mustafa

“It was a delightful experience publishing my manuscript with the Clinical Journal of Obstetrics and Gynecology. They offered me lots of opportunities I never had from most publishing houses and their prompt services are greatly appreciated.”

Department of Agricultural Economics, Agribusiness and Extension, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana

Akowuah Jones Asafo

View More

Related Journals

Help ?